NO20003721D0 - Farmasøytisk aktivt morfolinol - Google Patents

Farmasøytisk aktivt morfolinol

Info

Publication number: NO20003721D0
Authority: NO; Norway
Prior art keywords: pharmaceutically active; morpholinol; active morpholinol; pharmaceutically; active
Prior art date: 1998-01-21

Application number

NO20003721A

Other languages

English (en)

Other versions

NO326878B1 (no

NO20003721L (no

Inventor

Phillip Frederick Morgan

David Lee Musso

John Joseph Partidge

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

2000-07-20

Publication date

2000-07-20

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

2000-07-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-07-20 Publication of NO20003721D0 publication Critical patent/NO20003721D0/no

2000-09-19 Publication of NO20003721L publication Critical patent/NO20003721L/no

2009-03-09 Publication of NO326878B1 publication Critical patent/NO326878B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20003721A 1998-01-21 2000-07-20 Anvendelse av morfolinol NO326878B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22
PCT/US1999/001134 WO1999037305A1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Publications (3)

Publication Number	Publication Date
NO20003721D0 true NO20003721D0 (no)	2000-07-20
NO20003721L NO20003721L (no)	2000-09-19
NO326878B1 NO326878B1 (no)	2009-03-09

Family

ID=26312986

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20003721A NO326878B1 (no)	1998-01-21	2000-07-20	Anvendelse av morfolinol
NO20083529A NO20083529L (no)	1998-01-21	2008-08-14	Farmasoytisk aktivt morfolinol

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20083529A NO20083529L (no)	1998-01-21	2008-08-14	Farmasoytisk aktivt morfolinol

Country Status (30)

Country	Link
US (2)	US6274579B1 (no)
EP (2)	EP1047428B1 (no)
JP (1)	JP2002501025A (no)
KR (1)	KR100568063B1 (no)
CN (2)	CN1203858C (no)
AP (1)	AP1229A (no)
AT (1)	ATE365042T1 (no)
AU (1)	AU755536B2 (no)
BR (1)	BR9907203A (no)
CA (1)	CA2318268A1 (no)
CY (1)	CY1106828T1 (no)
DE (1)	DE69936335T2 (no)
DK (1)	DK1047428T3 (no)
EA (1)	EA002410B1 (no)
EE (1)	EE04452B1 (no)
ES (1)	ES2288012T3 (no)
HR (2)	HRP20051024A2 (no)
HU (1)	HUP0100900A3 (no)
ID (1)	ID26334A (no)
IL (2)	IL161942A0 (no)
IS (1)	IS2494B (no)
NO (2)	NO326878B1 (no)
NZ (3)	NZ520349A (no)
PL (1)	PL193622B1 (no)
PT (1)	PT1047428E (no)
SG (1)	SG115489A1 (no)
SK (1)	SK10912000A3 (no)
TR (1)	TR200002126T2 (no)
WO (1)	WO1999037305A1 (no)
YU (1)	YU67102A (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en) *	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
CA2318921A1 (en) *	1998-01-29	1999-08-05	John R. Mccullough	Pharmacological uses of optically pure (+)-bupropion
WO1999038504A1 (en)	1998-01-29	1999-08-05	Sepracor Inc.	Pharmaceutical uses of optically pure (-)-bupropion
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
EP1220673A2 (en) *	1999-10-13	2002-07-10	Glaxo Group Limited	Morpholinol derivatives for the treatment of obesity
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
CA2365428C (en) *	2000-12-21	2008-10-21	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
WO2003097046A1 (en) *	2002-05-17	2003-11-27	Duke University	Method for treating obesity
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
DE60324685D1 (de) *	2002-08-23	2008-12-24	Lilly Co Eli	2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
DE602004012403T2 (de) *	2003-04-29	2009-03-19	Orexigen Therapeutics, Inc., La Jolla	Zusammensetzungen zur beeinflussung des gewichtsverlusts
JP2007509855A (ja) *	2003-10-27	2007-04-19	スミスクラインビーチャムコーポレーション	（＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するためのジアステレオマー動的速度論分割プロセス
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
BRPI0506829A (pt) *	2004-01-13	2007-05-29	Univ Duke	composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20050277579A1 (en) *	2004-05-03	2005-12-15	Ranga Krishnan	Compositions for affecting weight loss
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
PL2135603T3 (pl)	2005-11-22	2013-09-30	Orexigen Therapeutics Inc	Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007079470A2 (en)	2006-01-03	2007-07-12	Algebra, Inc.	Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
EP2089005B1 (en)	2006-11-09	2010-03-17	Orexigen Therapeutics, Inc.	Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
TW200829235A (en)	2006-11-09	2008-07-16	Orexigen Therapeutics Inc	Methods for administering weight loss medications
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
EP2419400A1 (en)	2009-04-15	2012-02-22	Research Triangle Institute	Monoamine reuptake inhibitors
JP6196041B2 (ja)	2010-01-11	2017-09-13	オレキシジェン・セラピューティクス・インコーポレーテッド	大うつ病を有する患者において減量療法を提供する方法
CA2800219C (en) *	2010-05-21	2019-03-12	Research Triangle Institute	1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
JP2013526583A (ja)	2010-05-21	2013-06-24	リサーチ・トライアングル・インスティチュート	フェニルモルホリンおよびその類似体
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
CA2875056C (en)	2012-06-06	2024-03-26	Orexigen Therapeutics, Inc.	Methods of treating overweight and obesity
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) *	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2002501025A (ja)	2002-01-15
AP2000001869A0 (en)	2000-09-30
DK1047428T3 (da)	2007-10-08
CY1106828T1 (el)	2012-05-23
EE200000438A (et)	2001-12-17
CN1255389C (zh)	2006-05-10
AU2328099A (en)	1999-08-09
CN1294513A (zh)	2001-05-09
CN1528753A (zh)	2004-09-15
WO1999037305A1 (en)	1999-07-29
HRP20000494A2 (en)	2000-12-31
IS5568A (is)	2000-07-20
BR9907203A (pt)	2000-10-17
PL342012A1 (en)	2001-05-07
CA2318268A1 (en)	1999-07-29
ES2288012T3 (es)	2007-12-16
EP1047428A4 (en)	2001-12-19
HUP0100900A2 (hu)	2002-05-29
AP1229A (en)	2003-12-04
SG115489A1 (en)	2005-10-28
IL137346A0 (en)	2001-07-24
ID26334A (id)	2000-12-14
DE69936335T2 (de)	2008-02-28
HRP20000494B1 (en)	2009-02-28
IS2494B (is)	2009-02-15
PT1047428E (pt)	2007-09-07
US6274579B1 (en)	2001-08-14
CN1203858C (zh)	2005-06-01
EP1829544A1 (en)	2007-09-05
KR100568063B1 (ko)	2006-04-07
HUP0100900A3 (en)	2002-08-28
SK10912000A3 (sk)	2001-04-09
KR20010034285A (ko)	2001-04-25
NO20083529L (no)	2000-09-19
IL161942A0 (en)	2005-11-20
NO326878B1 (no)	2009-03-09
HRP20051024A2 (hr)	2006-04-30
PL193622B1 (pl)	2007-02-28
YU67102A (sh)	2004-12-31
EP1047428B1 (en)	2007-06-20
ATE365042T1 (de)	2007-07-15
DE69936335D1 (de)	2007-08-02
AU755536B2 (en)	2002-12-12
EA002410B1 (ru)	2002-04-25
TR200002126T2 (tr)	2000-12-21
NO20003721L (no)	2000-09-19
US6391875B2 (en)	2002-05-21
EA200000691A1 (ru)	2001-04-23
NZ520349A (en)	2004-02-27
NZ505809A (en)	2002-09-27
NZ529316A (en)	2004-05-28
EP1047428A1 (en)	2000-11-02
EE04452B1 (et)	2005-04-15
US20020019396A1 (en)	2002-02-14

Publication	Publication Date	Title
NO20003721D0 (no)	2000-07-20	Farmasøytisk aktivt morfolinol
PT1220856E (pt)	2005-02-28	Compostos farmaceuticamente activos
NL350038I1 (nl)	2008-12-01	Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazoline derivaten
DE69926752D1 (de)	2005-09-22	Therapeutisch wirksame biaryl-derivate
GB9823101D0 (en)	1998-12-16	Pharmaceutically active compounds
DE50007846D1 (de)	2004-10-28	Dreschkorb
DE60009395D1 (de)	2004-05-06	Bildanzeige
MA26473A1 (fr)	2004-12-20	Composes pharmacologiquement actifs.
DK1218374T3 (da)	2005-12-27	Farmaceutisk aktive sulfonamidderivater
NO992692L (no)	1999-12-06	Nefadozon doseringsform
NO993443L (no)	2000-01-14	Kabinstruktur
GB9823102D0 (en)	1998-12-16	Pharmaceutically active compounds
NO20012965D0 (no)	2001-06-15	Sulfonyloksazolaminer som terapeutisk aktive forbindelser
DE50015795D1 (de)	2009-12-24	Sektionaltor
DE59902159D1 (de)	2002-08-29	Aktiver mikromischer
FI991568A7 (fi)	1999-07-08	Farmaseuttisesti aktiivisia trisyklisiä amiineja
NO20005769D0 (no)	2000-11-14	Cyklosporinderivater
DE59903807D1 (de)	2003-01-30	Wirkstoffkonzentrat
EP1157700A4 (en)	2003-06-18	ANTI-HIV SUBSTANCE
SE9802539D0 (sv)	1998-07-13	New pharmaceutically active compounds
IS8740A (is)	2008-06-27	Lyfjafræðilega virkt morfólínól
SE9700660D0 (sv)	1997-02-25	Pharmaceutically active compounds
ATA203199A (de)	2001-03-15	Ablauf
SE9704874D0 (sv)	1997-12-23	New pharmaceutically active compounds
DE60004561D1 (de)	2003-09-18	Aktive baugruppe

Legal Events

Date	Code	Title	Description
2013-08-26	MM1K	Lapsed by not paying the annual fees